Latest & greatest articles for gabapentin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on gabapentin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on gabapentin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for gabapentin

1. Pregabalin (Lyrica or other brands) and gabapentin (Neurontin or other brands): known dangers and uncertainties during pregnancy

Pregabalin (Lyrica or other brands) and gabapentin (Neurontin or other brands): known dangers and uncertainties during pregnancy Prescrire IN ENGLISH - Spotlight ''Pregabalin (Lyrica° or other brands) and gabapentin (Neurontin° or other brands): known dangers and uncertainties during pregnancy'', 1 May 2020 {1} {1} {1} | | > > > Pregabalin (Lyrica° or other brands) and gabapentin (Neurontin° or other brands): known dangers and uncertainties during pregnancy Spotlight Every month, the subjects (...) in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Pregabalin (Lyrica° or other brands) and gabapentin (Neurontin° or other brands): known dangers and uncertainties during pregnancy Taken during pregnancy, pregabalin and gabapentin expose the newborn to harmful effects. Pregabalin and gabapentin are two very similar drugs which are widely used in France, particularly as antiepileptics and to treat

2020 Prescrire

2. Efficacy of Gabapentin for the Treatment of Alcohol Use Disorder in Patients With Alcohol Withdrawal Symptoms: A Randomized Clinical Trial

Efficacy of Gabapentin for the Treatment of Alcohol Use Disorder in Patients With Alcohol Withdrawal Symptoms: A Randomized Clinical Trial Efficacy of Gabapentin for the Treatment of Alcohol Use Disorder in Patients With Alcohol Withdrawal Symptoms: A Randomized Clinical Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go to . Clipboard, Search History, and several other (...) for external citation management software Create file Cancel Actions Cite Share Permalink Copy Page navigation JAMA Intern Med Actions . 2020 Mar 9;e200249. doi: 10.1001/jamainternmed.2020.0249. Online ahead of print. Efficacy of Gabapentin for the Treatment of Alcohol Use Disorder in Patients With Alcohol Withdrawal Symptoms: A Randomized Clinical Trial , , , , , , Affiliations Expand Affiliation 1 Addiction Sciences Division, Department of Psychiatry and Behavioral Sciences, Medical University of South

2020 EvidenceUpdates

3. Perioperative Gabapentin in Pediatric Thoracic Surgery Patients-Randomized, Placebo-Controlled, Phase 4 Trial (Abstract)

Perioperative Gabapentin in Pediatric Thoracic Surgery Patients-Randomized, Placebo-Controlled, Phase 4 Trial To determine whether the use of perioperative gabapentin reduces postoperative pain and anxiety, decreases ropivacaine consumption and side effects, and improves patient satisfaction.Randomized, placebo-controlled, phase 4 trial.Participants, care providers, investigators, data analysts.Department of Thoracic Surgery of the Institute of Tuberculosis and Lung Disease, Rabka Zdrój Branch (...) , Poland.Forty patients undergoing the Ravitch procedure.Patients aged nine to 17 years were randomized into a gabapentin (preoperative 15 mg/kg, treatment) or placebo group. Postoperative analgesia included gabapentin (7.5 mg/kg) or placebo two times per day for three days, epidural ropivacaine + fentanyl, paracetamol, nonsteroidal anti-inflammatory drugs, and metamizol as a "rescue drug." Pain, anxiety, analgesic consumption, side effects, and patient satisfaction were recorded.There was no statistically

2019 EvidenceUpdates

4. Pregabalin (Lyrica), gabapentin (Neurontin) and risk of abuse and dependence: new scheduling requirements from 1 April

Pregabalin (Lyrica), gabapentin (Neurontin) and risk of abuse and dependence: new scheduling requirements from 1 April Pregabalin (Lyrica), gabapentin (Neurontin) and risk of abuse and dependence: new scheduling requirements from 1 April - GOV.UK GOV.UK uses cookies to make the site simpler. or Search Pregabalin (Lyrica), gabapentin (Neurontin) and risk of abuse and dependence: new scheduling requirements from 1 April As of 1 April 2019, pregabalin and gabapentin are controlled under the Misuse (...) of Drugs Act 1971 as Class C substances and scheduled under the Misuse of Drugs Regulations 2001 as Schedule 3. Evaluate patients carefully for a history of drug abuse before prescribing pregabalin and gabapentin and observe patients for development of signs of abuse and dependence. Published 16 April 2019 From: Therapeutic area: , , , Contents Advice for healthcare professionals: to reflect growing concern about abuse, both pregabalin and gabapentin are now classified as Class C controlled substances

2019 MHRA Drug Safety Update

5. Gabapentin and pregabalin: Are high doses justified?

Gabapentin and pregabalin: Are high doses justified? Gabapentin and pregabalin: Are high doses justified? January 2019 Mailing Address: Therapeutics Initiative The University of British Columbia Department of Anesthesiology, Pharmacology & Therapeutics 2176 Health Sciences Mall Vancouver, BC Canada V6T 1Z3 Tel.: 604 822 0700 Fax: 604 822 0701 E-mail: info@ti.ubc.ca www.ti.ubc.ca 117 A nalgesia once seemed a relatively straightfor- ward aspect of medicine. Recommendations in textbooks (...) and guidelines were definitive, albeit heavily conflicted. Even recent guidelines encourage dose titration, based on an implicit, if unsupported, notion that more is likely to be better. 1 Recent experiments and systematic reviews show that drugs seldom outperform placebo significantly in chronic pain. Even old standards like acetaminophen and amitriptyline do not stand up well to careful scru- tiny of randomized placebo-controlled trials. 2,3 Recent evidence confirms that gabapentin and pregabalin

2019 Therapeutics Letter

6. Gabapentin

Gabapentin Top results for gabapentin - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4 (...) ) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for gabapentin The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you

2018 Trip Latest and Greatest

7. Gabapentin for Chronic Neuropathic Pain. (Abstract)

Gabapentin for Chronic Neuropathic Pain. Is gabapentin associated with pain relief in people with chronic neuropathic pain?Oral gabapentin (1200-3600 mg/d for 4-12 weeks) for patients with moderate or severe neuropathic pain from postherpetic neuralgia (PHN) or painful diabetic neuropathy (PDN) is associated with pain reduction of at least 50% in 14% to 17% more patients than placebo.

2018 JAMA

8. Effect of Perioperative Gabapentin on Postoperative Pain Resolution and Opioid Cessation in a Mixed Surgical Cohort: A Randomized Clinical Trial Full Text available with Trip Pro

Effect of Perioperative Gabapentin on Postoperative Pain Resolution and Opioid Cessation in a Mixed Surgical Cohort: A Randomized Clinical Trial Guidelines recommend using gabapentin to decrease postoperative pain and opioid use, but significant variation exists in clinical practice.To determine the effect of perioperative gabapentin on remote postoperative time to pain resolution and opioid cessation.A randomized, double-blind, placebo-controlled trial of perioperative gabapentin was conducted (...) of participants with continued pain or opioid use at 6 months and 1 year.Of 1805 patients screened for enrollment, 1383 were excluded, including 926 who did not meet inclusion criteria and 273 who declined to participate. Overall, 8% of patients randomized were lost to follow-up. A total of 202 patients were randomized to active placebo and 208 patients were randomized to gabapentin in the intention-to-treat analysis (mean [SD] age, 56.7 [11.7] years; 256 (62.4%) women and 154 (37.6%) men). Baseline

2018 EvidenceUpdates

9. Gabapentin for Adults with Neuropathic Pain: A Review of the Clinical Effectiveness

Gabapentin for Adults with Neuropathic Pain: A Review of the Clinical Effectiveness Gabapentin for Adults with Neuropathic Pain: A Review of the Clinical Effectiveness | CADTH.ca Find the information you need Gabapentin for Adults with Neuropathic Pain: A Review of the Clinical Effectiveness Gabapentin for Adults with Neuropathic Pain: A Review of the Clinical Effectiveness Last updated: March 12, 2018 Project Number: RC0970-000 Product Line: Research Type: Drug Report Type: Summary (...) with Critical Appraisal Result type: Report Question What is the clinical effectiveness of gabapentin for adults with neuropathic pain? Key Message The findings from four systematic reviews and one RCT for gabapentin (GBP) compared to placebo or active comparators is limited by quantity and quality of evidence for studies on neuropathic pain associated with conditions including chronic lower back pain, fibromyalgia, mixed neuropathic pain, and nerve injury pain. While some studies reported little

2018 Canadian Agency for Drugs and Technologies in Health - Rapid Review

10. Multiple sclerosis: Gabapentin

Multiple sclerosis: Gabapentin Gabapentin | Prescribing information | Multiple sclerosis | CKS | NICE Search CKS… Menu Gabapentin Multiple sclerosis: Gabapentin Last revised in October 2019 Gabapentin The use of gabapentin for spasticity and for oscillopsia in people with multiple sclerosis is off-label. For detailed prescribing information, see the section on in the CKS topic on . © .

2018 NICE Clinical Knowledge Summaries

11. Palliative cancer care - pain: What issues should I consider before prescribing gabapentin?

Palliative cancer care - pain: What issues should I consider before prescribing gabapentin? Gabapentin | Prescribing information | Palliative cancer care - pain | CKS | NICE Search CKS… Menu Gabapentin Palliative cancer care - pain: What issues should I consider before prescribing gabapentin? Last revised in October 2016 What issues should I consider before prescribing gabapentin? For prescribing information, see the section on in the CKS topic on . © .

2018 NICE Clinical Knowledge Summaries

12. Gabapentin (Neurontin): risk of severe respiratory depression

Gabapentin (Neurontin): risk of severe respiratory depression Gabapentin (Neurontin): risk of severe respiratory depression - GOV.UK GOV.UK uses cookies to make the site simpler. Search Gabapentin (Neurontin): risk of severe respiratory depression Gabapentin has been associated with a rare risk of severe respiratory depression even without concomitant opioid medicines. Patients with compromised respiratory function, respiratory or neurological disease, renal impairment, concomitant use (...) of central nervous system (CNS) depressants, and elderly people might be at higher risk of experiencing severe respiratory depression. Dose adjustments might be necessary in these patients. Published 26 October 2017 From: Therapeutic area: , Contents Advice for healthcare professionals: be aware of the risk of CNS depression, including severe respiratory depression, with gabapentin consider whether dose adjustments might be necessary in patients at higher risk of respiratory depression, including elderly

2017 MHRA Drug Safety Update

13. Comparison of the effect of topiramate versus gabapentin on neuropathic pain in patients with polyneuropathy: A randomized clinical trial Full Text available with Trip Pro

Comparison of the effect of topiramate versus gabapentin on neuropathic pain in patients with polyneuropathy: A randomized clinical trial Neuropathic pain is one of the most common complaints of neurologic clinics. Neuropathic pain is common and important and has inappropriate complications, and despite their importance, there is no effective treatment for them.Because of the importance of neuropathic pain and safe and effective treatment, in this study, we determined the effect of topiramate (...) versus gabapentin in patients with neuropathic pain.In this randomized clinical trial, 30 patients with pain attributed to neuropathy who had at least one month of neuropathic pain in one area, were randomized to receive either gabapentin, titrated from 300 mg/day to a maximum of 900 mg/day or topiramate, titrated from 50 mg/day to a maximum of 100 mg/day after a 4-week period in the neurology clinic of Imam Khomeini Hospital of Urmia city, Iran in 2015. Complication, drug tolerance rate and pain

2017 Electronic physician Controlled trial quality: uncertain

14. Abuse and Misuse of Gabapentin: Clinical Evidence, Safety, and Guidelines

Abuse and Misuse of Gabapentin: Clinical Evidence, Safety, and Guidelines Abuse and Misuse of Gabapentin: Clinical Evidence, Safety, and Guidelines | CADTH.ca Find the information you need Abuse and Misuse of Gabapentin: Clinical Evidence, Safety, and Guidelines Abuse and Misuse of Gabapentin: Clinical Evidence, Safety, and Guidelines Published on: October 19, 2017 Project Number: RB1146-000 Product Line: Research Type: Drug Report Type: Summary of Abstracts Result type: Report Question What (...) is the clinical evidence for the potential misuse or abuse of gabapentin? What are the harms associated with the potential misuse or abuse of gabapentin? What are the evidence-based guidelines regarding managing patients abusing gabapentin? Key Message Three systematic reviews and three non-randomized studies were identified regarding the potential abuse and misuse of gabapentin. Tags street drugs, substance abuse detection, substance abuse treatment centers, addiction, gabapentin Files Rapid Response Summary

2017 Canadian Agency for Drugs and Technologies in Health - Rapid Review

15. Perioperative Gabapentin Does Not Reduce Postoperative Delirium in Older Surgical Patients: A Randomized Clinical Trial Full Text available with Trip Pro

Perioperative Gabapentin Does Not Reduce Postoperative Delirium in Older Surgical Patients: A Randomized Clinical Trial Postoperative pain and opioid use are associated with postoperative delirium. We designed a single-center, randomized, placebo-controlled, parallel-arm, double-blinded trial to determine whether perioperative administration of gabapentin reduced postoperative delirium after noncardiac surgery.Patients were randomly assigned to receive placebo (N = 347) or gabapentin 900 mg (N (...) = 350) administered preoperatively and for the first 3 postoperative days. The primary outcome was postoperative delirium as measured by the Confusion Assessment Method. Secondary outcomes were postoperative pain, opioid use, and length of hospital stay.Data for 697 patients were included, with a mean ± SD age of 72 ± 6 yr. The overall incidence of postoperative delirium in any of the first 3 days was 22.4% (24.0% in the gabapentin and 20.8% in the placebo groups; the difference was 3.20%; 95% CI

2017 EvidenceUpdates

16. Gabapentin, Celecoxib, and Acetaminophen for the Prevention of Post-Operative Pain: Clinical Effectiveness

Gabapentin, Celecoxib, and Acetaminophen for the Prevention of Post-Operative Pain: Clinical Effectiveness Gabapentin, Celecoxib, and Acetaminophen for the Prevention of Post-Operative Pain: Clinical Effectiveness | CADTH.ca Find the information you need Gabapentin, Celecoxib, and Acetaminophen for the Prevention of Post-Operative Pain: Clinical Effectiveness Gabapentin, Celecoxib, and Acetaminophen for the Prevention of Post-Operative Pain: Clinical Effectiveness Published on: July 31, 2017 (...) Project Number: RB1124-000 Product Line: Research Type: Drug Report Type: Summary of Abstracts Result type: Report Question What is the clinical effectiveness of pre-operative administration of gabapentin to reduce post-operative pain following orthopedic surgery? What is the clinical effectiveness of pre-operative administration of celecoxib to reduce post-operative pain following orthopedic surgery? What is the clinical effectiveness of pre-operative administration of acetaminophen to reduce post

2017 Canadian Agency for Drugs and Technologies in Health - Rapid Review

17. Adjunctive pregabalin vs gabapentin for focal seizures: Interpretation of comparative outcomes Full Text available with Trip Pro

Adjunctive pregabalin vs gabapentin for focal seizures: Interpretation of comparative outcomes To evaluate the comparative safety and adjunctive efficacy of pregabalin and gabapentin in reducing seizure frequency in patients with partial-onset seizures based on prestudy modeling showing superior efficacy for pregabalin.The design of this comparative efficacy and safety study of pregabalin and gabapentin as adjunctive treatment in adults with refractory partial-onset seizures was randomized (...) , flexible dose, double blind, and parallel group. The study included a 6-week baseline and a 21-week treatment phase. The primary endpoint was the percentage change from baseline in 28-day seizure rate to the treatment phase.A total of 484 patients were randomized to pregabalin (n = 242) or gabapentin (n = 242). Of these, 359 patients (187 pregabalin, 172 gabapentin) completed the treatment phase. The observed median and mean in percentage change from baseline was -58.65 and -47.7 (SD 48.3

2016 EvidenceUpdates Controlled trial quality: predicted high

18. Gabapentin for HIV-associated Neuropathic Pain: A Review of the Clinical Effectiveness

Gabapentin for HIV-associated Neuropathic Pain: A Review of the Clinical Effectiveness Gabapentin for HIV-associated Neuropathic Pain: A Review of the Clinical Effectiveness | CADTH.ca Find the information you need Gabapentin for HIV-associated Neuropathic Pain: A Review of the Clinical Effectiveness Gabapentin for HIV-associated Neuropathic Pain: A Review of the Clinical Effectiveness Published on: January 22, 2016 Project Number: RC0750-000 Product Line: Research Type: Drug Report Type (...) : Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of gabapentin for the treatment of HIV-associated neuropathic pain? Key Message There is limited evidence for the use of gabapentin for the treatment of HIV-associated neuropathy. One relevant RCT, included in a systematic review, and one non-randomized study were identified. The studies suggest that gabapentin may improve pain and related sleep disturbances caused by HIV-associated sensory neuropathy

2016 Canadian Agency for Drugs and Technologies in Health - Rapid Review

19. Neuropathic pain - drug treatment: Gabapentin

Neuropathic pain - drug treatment: Gabapentin Gabapentin | Prescribing information | Neuropathic pain - drug treatment | CKS | NICE Search CKS… Menu Gabapentin Neuropathic pain - drug treatment: Gabapentin Last revised in February 2020 Gabapentin Is gabapentin licensed for neuropathic pain? Gabapentin is licensed for the treatment of peripheral neuropathic pain such as painful diabetic neuropathy and postherpetic neuralgia in adults [ ]. However, the National Institute for Health and Care (...) Excellence (NICE) recommends gabapentin as a first-line treatment option for adults with all neuropathic pain (except trigeminal neuralgia) [ ]. Dose and titration Fast titration (usually suitable for otherwise healthy younger adults). Initially, 300 mg once a day on day 1, then 300 mg twice a day on day 2, then 300 mg three times a day on day 3. Alternatively, start with 300 mg three times a day on day 1, then increase according to response in steps of 300 mg (in three divided doses) every 2–3 days up

2016 NICE Clinical Knowledge Summaries

20. Gabapentin for HIV-Associated Neuropathic Pain: Clinical Effectiveness

Gabapentin for HIV-Associated Neuropathic Pain: Clinical Effectiveness Gabapentin for HIV-Associated Neuropathic Pain: Clinical Effectiveness | CADTH.ca Find the information you need Gabapentin for HIV-Associated Neuropathic Pain: Clinical Effectiveness Gabapentin for HIV-Associated Neuropathic Pain: Clinical Effectiveness Published on: November 25, 2015 Project Number: RA0817-000 Product Line: Research Type: Drug Report Type: Reference List Result type: Report Question What is the clinical (...) effectiveness of gabapentin for the treatment of HIV-associated neuropathic pain? Key Message One systematic review, one randomized controlled trial, and one non-randomized study were identified regarding the clinical effectiveness of gabapentin for the treatment of HIV-associated neuropathic pain. Tags hiv, human immunodeficiency virus, human immunodeficiency viruses, neuralgia, pain management, hiv/aids, other miscellaneous topics, Neurontin, human immuno-deficiency virus, human immuno-deficiency viruses

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review